2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Amgen Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #48 · 安進公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | AMGN |
| Company | Amgen Inc. |
| GICS sector / industry | Health Care (XLV) / Biotechnology |
| S&P 500 rank (by weight) | #48 · 0.35% (Oct 28, 2026) |
| Sector rank | #7 in Health Care (Oct 28, 2026) |
| Headquarters | Thousand Oaks, California |
| Founded | 1980 |
| CEO | Robert A. Bradway (Chairman and CEO since 2012) |
| Employees | Approximately 28,000 (Dec 31, 2024) |
| Market cap | $244.27B (Oct 30, 2026) |
| Share price | $466.01 (Oct 30, 2026 close) |
| SEC filings | EDGAR — CIK 0000318154 |
WHAT IT DOES
Amgen is a biotechnology company. Its one-line model: discover, develop, manufacture and sell biologic and specialty medicines for serious illnesses.
Revenue comes from product sales through wholesalers, physicians, clinics, hospitals and pharmacies, led by a set of blockbuster medicines in bone health, cardiovascular disease, inflammation and oncology. Amgen manufactures much of its own product, unlike many biotech peers that outsource production.
The economics are patent- and pipeline-driven: a medicine's sales last while its patents hold, so research spending and new approvals must replace maturing products before biosimilars erode them.
BUSINESS SEGMENTS
| Prolia & Xgeva | Bone health medicines for osteoporosis and skeletal-related events in cancer. FY2024 product sales $6,599M. |
| Repatha | Cholesterol-lowering medicine for cardiovascular risk reduction. FY2024 product sales $2,222M. |
| Enbrel | Inflammatory disease medicine for rheumatoid arthritis, psoriasis and related conditions. FY2024 product sales $3,316M. |
| Otezla | Oral medicine for psoriasis and psoriatic arthritis. FY2024 product sales $2,126M. |
| Evenity | Bone-building medicine for osteoporosis in postmenopausal women at high fracture risk. FY2024 product sales $1,563M. |
| Tezspire | Severe asthma medicine developed with AstraZeneca. FY2024 product sales $972M. |
| Blincyto | Blood cancer medicine for acute lymphoblastic leukemia. FY2024 product sales $1,216M. |
HISTORY
| Year | Milestone |
|---|---|
| 1980 | Amgen is founded in Thousand Oaks, California. |
| 2012 | Robert A. Bradway becomes chairman and chief executive officer. |
| 2024 | Amgen reports record total revenues of $33.4 billion for 2024, with 14 blockbuster products. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $36.75B (FY2025 total revenues) |
| Operating income | $9.08B (FY2025 operating income) |
| Net income | $7.71B (FY2025 net income) |
| Diluted EPS | $14.23 (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Amgen is a mid-weight health care constituent: rank #48 by weight at 0.35% as of Oct 28, 2026, and #7 in Health Care. Its product sales and pipeline results are read as a gauge of biotechnology demand, and through it of innovation returns across the sector.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Amgen Q4 and full-year 2024 results release and 2024 shareholder letter |
| Index weight & ranks | Slickcharts S&P 500 weights, Oct 28, 2026 close, fetched Oct 29, 2026 |
| Market cap | $244.27B (Oct 30, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | AMGN |
| 公司 | Amgen(安進) |
| GICS 板塊/行業 | 醫療保健(XLV)/生物科技 |
| 標普500排名(按權重) | #48 · 0.35%(Oct 28, 2026) |
| 板塊內排名 | 醫療保健 #7(Oct 28, 2026) |
| 總部 | 美國加利福尼亞州千樽模斯 |
| 成立 | 1980年 |
| 執行長 | Robert A. Bradway(自2012年起出任董事長兼執行長) |
| 員工 | 約 28,000 人(2024 年 12 月 31 日) |
| 市值 | $244.27B(Oct 30, 2026) |
| 股價 | $466.01(Oct 30, 2026 收盤) |
| SEC 申報 | EDGAR — CIK 0000318154 |
業務概覽
Amgen 是一家生物科技公司。其一句話商業模式是:發現、開發、製造與銷售用於嚴重疾病的生物藥物與專科藥物。
收入來自透過批發商、醫師、診所、醫院與藥局銷售的產品,由骨骼健康、心血管、發炎與腫瘤領域的一批重磅藥物帶動。與許多將生產外包的生物科技同業不同,Amgen 自行製造大部分產品。
這種經濟由專利與產品線驅動:藥物的銷售在專利有效期間持續,故研發支出與新藥批准必須在生物相似藥侵蝕之前替代成熟產品。
業務板塊
| Prolia 與 Xgeva | 骨骼健康藥物,用於骨質疏騆與癌症相關骨骼事件。 2024 財年產品銷售額 65.99 億美元。 |
| Repatha | 降脂固醇藥物,用於降低心血管風險。 2024 財年產品銷售額 22.22 億美元。 |
| Enbrel | 發炎性疾病藥物,用於類風濕性關節炎、療癣及相關疾病。 2024 財年產品銷售額 33.16 億美元。 |
| Otezla | 口服藥物,用於療癣及療癣性關節炎。 2024 財年產品銷售額 21.26 億美元。 |
| Evenity | 骨骼生成藥物,用於高骨折風險的停經後骨質疏騆。 2024 財年產品銷售額 15.63 億美元。 |
| Tezspire | 嚴重哮喘藥物,與 AstraZeneca 合作開發。 2024 財年產品銷售額 9.72 億美元。 |
| Blincyto | 血液癌症藥物,用於急性淋巴樣白血病。 2024 財年產品銷售額 12.16 億美元。 |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1980 | Amgen 於加利福尼亞州千樽模斯成立。 |
| 2012 | Robert A. Bradway 出任董事長兼執行長。 |
| 2024 | Amgen 報告 2024 年總收入創紀錄 $33.4B,擁有 14 個重磅產品。 |
競爭地位
財務快照
| 總收入 | $36.75B(FY2025 總收入) |
| 營業利潤 | $9.08B(FY2025 營業利潤) |
| 淨利潤 | $7.71B(FY2025 淨利潤) |
| 稀釋 EPS | $14.23(FY2025 稀釋 EPS) |
主要風險
對標普500的重要性
Amgen 是權重中等的醫療保健成分股:按權重排名 #48,權重 0.35%(以 Oct 28, 2026 為準),醫療保健板塊內排名 #7。其產品銷售與產品線派績被視為生物科技需求的指標,並由此反映整個板塊的創新報酬。
來源與方法
| 財務、板塊、總部 | Amgen Q4 及 2024 年全年派績發佈及 2024 年股東信 |
| 指數權重與排名 | Slickcharts S&P 500 權重,Oct 28, 2026 收盤,Oct 29, 2026 抓取 |
| 市值 | $244.27B(Oct 30, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-29 17:29 · updated 2026-11-14 22:58 · rev 11